drugset / Trial / NCT00029289

Effects of Lutein in Retinitis Pigmentosa

NCT00029289

RandomizedCrossoverDouble-blindTreatment

Summary

Phase I/II double-masked, randomized, placebo-controlled, cross-over trial to determine effects of lutein on vision in retinitis pigmentosa, including safety and effective dosage assessment

Timeline

Start
2001-04
Primary completion
Completion
2002-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Lutein Other / unclassified 30 mg

Indications